Immune Modulatory Effects of Statins

Overview

Journal Immunology

Specialty Allergy & Immunology

Date 2018 Feb 3

PMID 29392731

Citations 121

Authors

Robert Zeiser

Affiliations

Soon will be listed here.

Abstract

Despite major advances in recent years, immunosuppressive regimens for multiple sclerosis, rheumatoid arthritis, systemic lupus erythematosus and graft-versus-host disease still have major adverse effects and immunomodulation rather than immune paralysis would be desirable. Statins inhibit the rate-limiting enzyme of the l-mevalonate pathway, the 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase. It was shown that blocking the l-mevalonate pathway reduces inflammation through effects on downstream metabolites of the pathway including farnesylpyrophosphates and geranylgeranylpyrophosphates, which are essential for the attachment of GTPases like RhoA, Rac and Ras to the cell membrane. Therefore, l-mevalonate pathway downstream products play critical roles in the different steps of an immune response including immune cell activation, migration, cytokine production, immune metabolism and survival. This review discusses the relevance of the different metabolites for the immunomodulatory effect of statins and connects preclinical results with data from clinical studies that tested statins for the treatment of different inflammatory diseases.

Citing Articles

Recent advances in nutritional metabolism studies on SARS-CoV-2 infection.

Jiang Y, Xu L, Zheng X, Shi H Infect Med (Beijing). 2025; 4(1):100162.

PMID: 39936106 PMC: 11810712. DOI: 10.1016/j.imj.2025.100162.

Subgingival Delivery of Statins as an Adjunct in the Non-Surgical Treatment of Periodontitis: A Systematic Review.

Pietrzko M, Pietrzko M, Niemczyk W, Skaba D, Wiench R Biomedicines. 2025; 13(1).

PMID: 39857766 PMC: 11761576. DOI: 10.3390/biomedicines13010182.

Relationship Between T-helper 1 Inflammatory Biomarkers and Hematological Index Responses in Patients With Multiple Sclerosis.

Dezayee Z Cureus. 2025; 16(12):e75278.

PMID: 39764311 PMC: 11702979. DOI: 10.7759/cureus.75278.

Statins inhibit onco-dimerization of the 4Ig isoform of B7-H3.

Sutton M, Glazer S, Al Zaki A, Napoli A, Yang P, Bhosale P bioRxiv. 2025; .

PMID: 39763965 PMC: 11702627. DOI: 10.1101/2024.12.18.628944.

Association of higher potency statin use with risk of osteoporosis and fractures in patients with stroke in a Korean nationwide cohort study.

Jeong J, Noh Y, Cho S, Hsieh C, Cho Y, Shin J Sci Rep. 2024; 14(1):30825.

PMID: 39730536 PMC: 11680841. DOI: 10.1038/s41598-024-81628-z.

References

Rotta M, Storer B, Storb R, Martin P, Heimfeld S, Peffer A . Donor statin treatment protects against severe acute graft-versus-host disease after related allogeneic hematopoietic cell transplantation. Blood. 2009; 115(6):1288-95. PMC: 2826239. DOI: 10.1182/blood-2009-08-240358. View

Leung B, Sattar N, Crilly A, Prach M, McCarey D, Payne H . A novel anti-inflammatory role for simvastatin in inflammatory arthritis. J Immunol. 2003; 170(3):1524-30. DOI: 10.4049/jimmunol.170.3.1524. View

Pihl-Jensen G, Tsakiri A, Frederiksen J . Statin treatment in multiple sclerosis: a systematic review and meta-analysis. CNS Drugs. 2015; 29(4):277-91. DOI: 10.1007/s40263-015-0239-x. View

Zhao N, Dong Q, Qian C, Li S, Wu Q, Ding D . Lovastatin blocks Kv1.3 channel in human T cells: a new mechanism to explain its immunomodulatory properties. Sci Rep. 2015; 5:17381. PMC: 4663632. DOI: 10.1038/srep17381. View

Zeiser R, Youssef S, Baker J, Kambham N, Steinman L, Negrin R . Preemptive HMG-CoA reductase inhibition provides graft-versus-host disease protection by Th-2 polarization while sparing graft-versus-leukemia activity. Blood. 2007; 110(13):4588-98. PMC: 2234784. DOI: 10.1182/blood-2007-08-106005. View

Shimabukuro-Vornhagen A, Liebig T, von Bergwelt-Baildon M . Statins inhibit human APC function: implications for the treatment of GVHD. Blood. 2008; 112(4):1544-5. DOI: 10.1182/blood-2008-04-149609. View

Ferreira G, Navarro T, Telles R, Andrade L, Sato E . Atorvastatin therapy improves endothelial-dependent vasodilation in patients with systemic lupus erythematosus: an 8 weeks controlled trial. Rheumatology (Oxford). 2007; 46(10):1560-5. DOI: 10.1093/rheumatology/kem186. View

Zeiser R, Blazar B . Acute Graft-versus-Host Disease - Biologic Process, Prevention, and Therapy. N Engl J Med. 2017; 377(22):2167-2179. PMC: 6034180. DOI: 10.1056/NEJMra1609337. View

Youssef S, Stuve O, Patarroyo J, Ruiz P, Radosevich J, Hur E . The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature. 2002; 420(6911):78-84. DOI: 10.1038/nature01158. View

10.

Zeiser R, Blazar B . Pathophysiology of Chronic Graft-versus-Host Disease and Therapeutic Targets. N Engl J Med. 2017; 377(26):2565-2579. DOI: 10.1056/NEJMra1703472. View

11.

Kanate A, Hari P, Pasquini M, Visotcky A, Ahn K, Boyd J . Recipient Immune Modulation with Atorvastatin for Acute Graft-versus-Host Disease Prophylaxis after Allogeneic Transplantation. Biol Blood Marrow Transplant. 2017; 23(8):1295-1302. DOI: 10.1016/j.bbmt.2017.04.009. View

12.

van Leuven S, Mendez-Fernandez Y, Stroes E, Tak P, Major A . Statin therapy in lupus-mediated atherogenesis: two birds with one stone?. Ann Rheum Dis. 2010; 70(2):245-8. PMC: 3306212. DOI: 10.1136/ard.2010.133827. View

13.

Zipp F, Waiczies S, Aktas O, Neuhaus O, Hemmer B, Schraven B . Impact of HMG-CoA reductase inhibition on brain pathology. Trends Pharmacol Sci. 2007; 28(7):342-9. DOI: 10.1016/j.tips.2007.05.001. View

14.

Stuve O, Youssef S, Weber M, Nessler S, von Budingen H, Hemmer B . Immunomodulatory synergy by combination of atorvastatin and glatiramer acetate in treatment of CNS autoimmunity. J Clin Invest. 2006; 116(4):1037-44. PMC: 1401481. DOI: 10.1172/JCI25805. View

15.

McCarey D, McInnes I, Madhok R, Hampson R, Scherbakov O, Ford I . Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial. Lancet. 2004; 363(9426):2015-21. DOI: 10.1016/S0140-6736(04)16449-0. View

16.

Sahebkar A, Rathouska J, Derosa G, Maffioli P, Nachtigal P . Statin impact on disease activity and C-reactive protein concentrations in systemic lupus erythematosus patients: A systematic review and meta-analysis of controlled trials. Autoimmun Rev. 2016; 15(4):344-53. DOI: 10.1016/j.autrev.2015.12.007. View

17.

Zeiser R, Maas K, Youssef S, Durr C, Steinman L, Negrin R . Regulation of different inflammatory diseases by impacting the mevalonate pathway. Immunology. 2009; 127(1):18-25. PMC: 2678178. DOI: 10.1111/j.1365-2567.2008.03011.x. View

18.

Weber M, Prodhomme T, Youssef S, Dunn S, Steinman L, Zamvil S . Neither T-helper type 2 nor Foxp3+ regulatory T cells are necessary for therapeutic benefit of atorvastatin in treatment of central nervous system autoimmunity. J Neuroinflammation. 2014; 11:29. PMC: 3922392. DOI: 10.1186/1742-2094-11-29. View

19.

Graham K, Lee L, Higgins J, Steinman L, Utz P, Ho P . Failure of oral atorvastatin to modulate a murine model of systemic lupus erythematosus. Arthritis Rheum. 2008; 58(7):2098-104. PMC: 4143381. DOI: 10.1002/art.23605. View

20.

Kanda H, Yokota K, Kohno C, Sawada T, Sato K, Yamaguchi M . Effects of low-dosage simvastatin on rheumatoid arthritis through reduction of Th1/Th2 and CD4/CD8 ratios. Mod Rheumatol. 2007; 17(5):364-8. DOI: 10.1007/s10165-007-0589-4. View